Ondansetron and the risk of cardiac arrhythmias: A systematic review and postmarketing analysis

Annals of Emergency Medicine

Volumn 64, Issue 1, 2014, Pages

  Freedman, Stephen B ^a   Uleryk, Elizabeth ^b,d   Rumantir, Maggie ^c   Finkelstein, Yaron ^b,c,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIEMETIC AGENT; ELECTROLYTE; ONDANSETRON;

ADOLESCENT; ADULT; AGED; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL PRACTICE; DRUG SAFETY; DRUG USE; ELECTROCARDIOGRAPHY MONITORING; ELECTROLYTE BLOOD LEVEL; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPEREMESIS GRAVIDARUM; LONG QT SYNDROME; MEDICAL HISTORY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE VOMITING; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK; SCREENING; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ANTIEMETICS; ARRHYTHMIAS, CARDIAC; EMERGENCY TREATMENT; HUMANS; MONITORING, PHYSIOLOGIC; ONDANSETRON; PRODUCT SURVEILLANCE, POSTMARKETING; RISK;

EID: 84903171167     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2013.10.026     Document Type: Article

References (57)

1. J.C. Bryson Clinical safety of ondansetron Semin Oncol 19 1992 26 32
2. K.Y. Tay, M.B. Ewald, and F.T. Bourgeois Use of QT-prolonging medications in US emergency departments, 1995-2009 Pharmacoepidemiol Drug Saf 2013 10.1002/pds.3455
3. J.J. Sturm, D.A. Hirsh, and A. Schweickert et al. Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses? Ann Emerg Med 55 2010 415 422
4. Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms may be associated with use of Zofran (ondansetron). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm271913.htm. Accessed April 23, 2013.
5. FDA drug safety podcast for healthcare professionals: new information regarding QT prolongation with ondansetron (Zofran). Available at: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm310546.htm. Accessed September 5, 2012.
6. Zofran (ondansetron) - association with changes in electrical activity in the heart - for health professionals. Available at: http://www. healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/15080a-eng.php. Accessed April 23, 2013.
7. Medicines and Healthcare Products Regulatory Agency. Ondansetron (Zofran): risk of QTc prolongation - important new intravenous dose restriction. Available at: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ CON180635. Accessed April 23, 2013.
8. C.M. Hohl, J. Dankoff, and A. Colacone et al. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department Ann Emerg Med 38 2001 666 671
9. A. Banerjee, D. Mbamalu, and S. Ebrahimi et al. The prevalence of polypharmacy in elderly attenders to an emergency department - a problem with a need for an effective solution Int J Emerg Med 4 2011 22
10. J.S. Olshaker, and J.D. Mason The usefulness of serum electrolytes in the evaluation of acute adult gastroenteritis Ann Emerg Med 18 1989 258 260
11. A. Garson Jr., M. Dick 2nd, and A. Fournier et al. The long QT syndrome in children. An international study of 287 patients Circulation 87 1993 1866 1872
12. A.M. Rodday, J.K. Triedman, and M.E. Alexander et al. Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: a meta-analysis Pediatrics 129 2012 e999 e1010
13. E. Bruzzese, A.L. Vecchio, and A. Guarino Hospital management of children with acute gastroenteritis Curr Opin Gastroenterol 29 2013 23 30
14. D. Moher, A. Liberati, and J. Tetzlaff et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269 W64
15. A. Liberati, D.G. Altman, and J. Tetzlaff et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
16. V. Alberani, P. De Castro Pietrangeli, and A.M. Mazza The use of grey literature in health sciences: a preliminary survey Bull Med Libr Assoc 78 1990 358 363
17. G. Wahi, P.C. Parkin, and J. Beyene et al. Effectiveness of interventions aimed at reducing screen time in children: a systematic review and meta-analysis of randomized controlled trials Arch Pediatr Adolesc Med 165 2011 979 986
18. M. Lindquist VigiBase, the WHO Global ICSR Database System: basic facts Drug Inf J 42 2008 409 419
19. C.A. Naranjo, U. Busto, and E.M. Sellers et al. A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther 30 1981 239 245
20. M. Avner, Y. Finkelstein, and D. Hackam et al. Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale Paediatr Drugs 9 2007 267 270
21. M. Rezvani, Y. Finkelstein, and Z. Verjee et al. Generalized seizures following topical lidocaine administration during circumcision: establishing causation Paediatr Drugs 9 2007 125 127
22. R.H. Meyboom, Y.A. Hekster, and A.C. Egberts et al. Causal or casual? the role of causality assessment in pharmacovigilance Drug Saf 17 1997 374 389
23. R. Chandrakala, C. Vijayashankara, and K. Kumar et al. Ondansetron induced fatal ventricular tachycardia Indian J Pharmacol 40 2008 186 187
24. P.L. Havrilla, S.L. Kane-Gill, and M.M. Verrico et al. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy Ann Pharmacother 43 2009 532 536
25. N. Afonso, A. Dang, and V. Namshikar et al. Intravenous ondansetron causing severe bradycardia: two cases Ann Card Anaesth 12 2009 172 173
26. K. McKechnie, and A. Froese Ventricular tachycardia after ondansetron administration in a child with undiagnosed long QT syndrome Can J Anaesth 57 2010 453 457
27. R. Bagatell, M. Hainstock, and M.C. Lowe et al. The perfect storm: torsades de pointes in a child with leukemia Pediatr Blood Cancer 49 2007 996 999
28. E.K. Choo, F.S. Weber, and T.A. Schmidt Torsade de pointes after administration of droperidol for nausea and vomiting Prehosp Emerg Care 13 2009 261 265
29. W.A. Baguley, W.T. Hay, and K.P. Mackie et al. Cardiac dysrhythmias associated with the intravenous administration of ondansetron and metoclopramide Anesth Analg 84 1997 1380 1381
30. C. Chakraborti, and J. Egan The lesser of two adverse reactions Joint Commission J Qual Pat Saf 36 2010 22 27
31. N.S. Kasinath, O. Malak, and J. Tetzlaff Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report Can J Anaesth 50 2003 229 231
32. M.S. Moazzam, F. Nasreen, and S. Bano et al. Symptomatic sinus bradycardia: a rare adverse effect of intravenous ondansetron Saudi J Anaesth 5 2011 96 97
33. S. Dolenska Intraoperative cardiac arrest in acquired long QT syndrome Br J Anaesth 102 2009 503 505
34. A. Perez-Verdia, F. Angulo, and F.L. Hardwicke et al. Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature Pharmacotherapy 25 2005 1271 1276
35. V. Bosek, P. Hu, and L.A. Robinson Acute myocardial ischemia after administration of ondansetron hydrochloride Anesthesiology 92 2000 885 887
36. H.S. Ballard, G. Bottino, and J. Bottino Ondansetron and chest pain Lancet 340 1992 1107
37. J.A. Purvis, E.L. Cunningham, and P.G. McGlinchey et al. Drugs, electrolytes and tako-tsubo cardiomyopathy: triple aetiology of acquired long QT syndrome and torsades de pointes Ulster Med J 78 2009 188 189
38. A. Hussain, and S. Ghazal After more than 300 defibrillation shocks, patient still alive 12 years later refractory torsade de pointes due to polypharmacy and persistent vomiting J Saudi Heart Assoc 22 2010 149 151
39. J.A. Philips, F.M. Marty, and R.M. Stone et al. Torsades de pointes associated with voriconazole use Transpl Infect Dis 9 2007 33 36
40. Boxall E, Milne J, Peters E, et al. Sudden unexplained death in a patient with HIV and MDR-TB. Journal of the International AIDS Society Conference: 10th International Congress on Drug Therapy in HIV Infection; Conference Start 2010; 20101107; Glasgow, Scotland, November 7-11, 2010.
41. A.T. Nathan, D.H. Berkowitz, and L.M. Montenegro et al. Implications of anesthesia in children with long QT syndrome Anesth Analg 112 2011 1163 1168
42. A. Saxena, T. Chand, and S.K. Arya et al. Ondansetron-induced ventricular tachycardia in a patient of caesarian section J Obstet Anaesth Crit Care 2 2012 103 104
43. D.M. Roden Drug-induced prolongation of the QT interval N Engl J Med 350 2004 1013 1022
44. R.M. Gallagher, J.J. Kirkham, and J.R. Mason et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool PLoS One 6 2011 e28096
45. S.L. Kane-Gill, L. Kirisci, and D.S. Pathak Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit? Ann Pharmacother 39 2005 1823 1827
46. GlaxoSmithKline Inc., inventor Product Monograph - Zofran (ondansetron hydrochloride dihydrate). Mississauga, ON January 26, 2012.
47. A.B. Kharbanda, M. Hall, and S.S. Shah et al. Variation in resource utilization across a national sample of pediatric emergency departments J Pediatr 163 2013 230 236
48. S. Madjunkova, C. Maltepe, and G. Koren The leading concerns of American women with nausea and vomiting of pregnancy calling Motherisk NVP Helpline Obstet Gynecol Int 2013 2013 752980
49. B. Pasternak, H. Svanstrom, and A. Hviid Ondansetron in pregnancy and risk of adverse fetal outcomes N Engl J Med 368 2013 814 823
50. S.H. Raymond A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia Aust N Z J Obstet Gynaecol 53 2013 358 362
51. The effect of intravenous ondansetron on the QT interval of patients' electrocardiograms in the pediatric emergency department. Available at: http://www2.aap.org/sections/pem/PDF/2013SOEMNCEProgram7-13.pdf. Accessed July 29, 2013.
52. J.F. Pritchard, J.C. Bryson, and A.E. Kernodle et al. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers Clin Pharmacol Ther 51 1992 51 55
53. C.M. VanDenBerg, Y. Kazmi, and J. Stewart et al. Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository, and i.v. infusion Am J Health Syst Pharm 57 2000 1046 1050
54. B. Charbit, P. Albaladejo, and C. Funck-Brentano et al. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron Anesthesiology 102 2005 1094 1100
55. B. Charbit, J.C. Alvarez, and E. Dasque et al. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study Anesthesiology 109 2008 206 212
56. GlaxoSmithKline Inc. A randomized, double-blind, four-period crossover study to investigate the effect of intravenous ondansetron, a 5-HT3 antagonist, on cardiac conduction as compared to placebo and moxifloxacin in healthy adult subjects. Available at: http://www.gsk-clinicalstudyregister.com/result-detail. jsp?protocolId=115458&studyId=9B2760D1-7F0C-4871-992F- EAF86227CE3E&compound=ondansetron. Accessed October 1, 2012.
57. N. Ghafouri, M.A. Darracq, and F.L. Cantrell Ondansetron-associated hypotension following pediatric self-poisoning Pediatr Emerg Care 28 2012 596 597